risperidone has been researched along with Astrocytoma, Grade IV in 3 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect." | 5.51 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. ( Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T, 2019) |
| "Temozolomide (TMZ) has been the first-line chemotherapeutic agent used, although to achieve a satisfactory clinical effect." | 1.51 | Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists. ( Gao, L; Huang, X; Jiang, X; Li, J; Liu, X; Liu, Z; Zeng, T, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Y | 1 |
| Wang, T | 1 |
| Wan, Q | 1 |
| Wang, Q | 1 |
| Chen, Z | 1 |
| Gao, Y | 1 |
| Ye, Y | 1 |
| Lin, J | 1 |
| Zhao, B | 1 |
| Wang, H | 1 |
| Yang, J | 1 |
| Zhao, K | 1 |
| Lu, N | 1 |
| Liu, Z | 1 |
| Jiang, X | 1 |
| Gao, L | 1 |
| Liu, X | 1 |
| Li, J | 1 |
| Huang, X | 1 |
| Zeng, T | 1 |
| Lee, MA | 1 |
| Leng, ME | 1 |
| Tiernan, EJ | 1 |
3 other studies available for risperidone and Astrocytoma, Grade IV
| Article | Year |
|---|---|
TRAF4 Maintains Deubiquitination of Caveolin-1 to Drive Glioblastoma Stemness and Temozolomide Resistance.
Topics: Brain Neoplasms; Caveolin 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Glioblastoma; Humans; Neop | 2022 |
Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
Topics: Animals; Antineoplastic Agents, Alkylating; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proli | 2019 |
Risperidone: a useful adjunct for behavioural disturbance in primary cerebral tumours.
Topics: Adult; Antipsychotic Agents; Behavioral Symptoms; Brain Neoplasms; Fatal Outcome; Glioblastoma; Huma | 2001 |